Author Archives: Gastroenterology Journal
Reply to GASTRO-D-21-03047: “The insightful clarification of miR-144 mediated metabolic dysfunction”
Posted in News
Comments Off on Reply to GASTRO-D-21-03047: “The insightful clarification of miR-144 mediated metabolic dysfunction”
Assessing the Impact of Changes to the Rome IV Criteria for Clinical Practice in Irritable Bowel Syndrome.
Posted in News
Comments Off on Assessing the Impact of Changes to the Rome IV Criteria for Clinical Practice in Irritable Bowel Syndrome.
“A T.E.A.M. Approach to Diversity, Equity and Inclusion in Gastroenterology and Hepatology”
Posted in News
Comments Off on “A T.E.A.M. Approach to Diversity, Equity and Inclusion in Gastroenterology and Hepatology”
Predicting pancreatic cancer in the UK Biobank cohort using polygenic risk scores and diabetes mellitus.
Diabetes mellitus (DM) is known to be associated with Pancreatic ductal adenocarcinoma (PDAC), particularly, new-onset DM (NODM). Others have developed polygenic risk scores (PRS) associated with PDAC risk. We aimed to compare the performance of these … Continue reading
Posted in News
Comments Off on Predicting pancreatic cancer in the UK Biobank cohort using polygenic risk scores and diabetes mellitus.
Predicting pancreatic cancer in the UK Biobank cohort using polygenic risk scores and diabetes mellitus.
Diabetes mellitus (DM) is known to be associated with Pancreatic ductal adenocarcinoma (PDAC), particularly, new-onset DM (NODM). Others have developed polygenic risk scores (PRS) associated with PDAC risk. We aimed to compare the performance of these … Continue reading
Posted in News
Comments Off on Predicting pancreatic cancer in the UK Biobank cohort using polygenic risk scores and diabetes mellitus.
Treatment of Type 1 Diabetes by Microbiome Maintenance
Posted in News
Comments Off on Treatment of Type 1 Diabetes by Microbiome Maintenance
Treatment of Type 1 Diabetes by Microbiome Maintenance
Posted in News
Comments Off on Treatment of Type 1 Diabetes by Microbiome Maintenance
Author response to “MELD 3.0: The Model for End-stage Liver Disease Updated for the Modern Era”
Posted in News
Comments Off on Author response to “MELD 3.0: The Model for End-stage Liver Disease Updated for the Modern Era”
A road less travelled: To a finite CHB therapy
Posted in News
Comments Off on A road less travelled: To a finite CHB therapy
Gestational insulin resistance is mediated by the gut microbiome-indoleamine 2,3-dioxygenase axis
Normal gestation involves reprogramming of maternal gut microbiome (GM) that contributes to maternal metabolic changes by unclear mechanisms. This study aimed to understand the mechanistic underpinnings of GM – maternal metabolism interaction. Continue reading
Posted in News
Comments Off on Gestational insulin resistance is mediated by the gut microbiome-indoleamine 2,3-dioxygenase axis